Nigeria: The Effects Of Parallel Importation On The Nigerian Healthcare Industry-II*

Last Updated: 17 May 2016
Article by Yetunde Okojie

Nigeria being a member of the World Trade Organisation (WTO) since 1st January 1995 is a signatory to the Agreement on Trade-Related Aspects of Intellectual Property Rights ('TRIPS Agreement'). The statutory framework in Nigeria regulating the implementation of the TRIPS Agreement, patent rights and access to medicines is the Patents and Designs Act.3 In 2008 a Bill4 was proposed to consolidate the administration and management of intellectual property rights within a single institutional framework. Although this Bill is yet to be adopted, it indicates the overall approach, which should be implemented in the imminent reform of the intellectual property framework in Nigeria.5

3:1 A review of Parallel Importation in Nigeria:

The Patents and Designs Act 1990 adopts the domestic or territorial exhaustion of rights principle6 by specifying that the patentees' rights are exhausted when the products covered by the patent are lawfully sold in Nigeria.7 Notwithstanding, Section 6(3)(b) of the Patents and Designs Act also offers an exemption to the exhaustion of rights of a patentee where the patentee "makes provision for a special application of the product". By virtue of this special application exception, the patentee's rights are reserved despite their exhaustion. This provision restricts and complicates the exhaustion of rights principle in Nigeria as it fails to clarify what would amount to a special application.

This restrictive approach towards exhaustion adopted by the Patents and Designs Act 1990 seems unnecessary as the TRIPS Agreement and the Doha Declaration allows WTO Members the freedom of choice and flexibility in terms of the exhaustion regime to be adopted at the national level, as discussed in the first part of this paper.8             

On the other hand, the IP Bill 2008 has adopted an international exhaustion regime for patent rights. Consequently, Article 112(3)(f) of the proposed Bill provides that rights afforded to a patent will not cover "an act done in respect of a product covered by the patent after the product has been lawfully sold in any country". This provision is much clearer than what is contained in the current Patent and Designs Act and if implemented, parallel importation of patented products in Nigeria would be permitted upon an initial sale of the product any place in the world.

3:2 A review of Compulsory Licensing in Nigeria:

Nigerian legislations governing intellectual property have come a long way from what was in operation prior to 1970, when the United Kingdom Patent Ordinance 19259 was enforced in Nigeria. An amendment in the Law came as a result of the decision of the High Court of Lagos State in the case of Rhone Poulenc and Anor v Lodeka Pharmacy.10 In this case, the defendant supplied the Ministry of Health with pharmaceuticals protected by a patent held by the plaintiff. After the first supply, the Ministry of Health ordered for a second supply of pharmaceuticals and the defendants imported the second supply without reference to the plaintiff.

The plaintiff subsequently brought an action for infringement and the defendant sought to rely on Section 46(1) of the Patent Act 1949,11 which provided that "any government department or any person authorized in writing by a government department may make, use and exercise any patented invention for the service of the crown". However, the High Court held that the content of Section 46 of the Patent Act 1949 did not extend to the defendants. Furthermore, the high court stated that the patent regime in operation in Nigeria did not confer on the Nigerian government the same rights given to the British Crown under the "Registration of United Kingdom Patent Ordinance 1925", which was at the time applicable to Nigeria.12

>This decision was understood by the Nigerian government as an affront to its sovereignty and consequently the government passed the Patent Rights (Limitation) Act,13 which granted the government and its agencies similar powers and rights as those possessed by the United Kingdom government under Section 46 of the Patent Act 1949.14 The Patent Rights (Limitation) Act 1968 was promulgated to enable the Nigerian government make use of certain inventions by third parties. The Limitation Act also made provision on how to use these inventions in emergencies.15 Even though Nigeria passed the Patent Limitation Act of 1968, the Patent Ordinance was still in force and an applicant for a patent still had to apply for registration in the United Kingdom before reregistering in Nigeria. This position was inconsistent with a sovereign status, and it was one of the reasons that led to the promulgation of the Patents and Designs Act of 1970 after Nigeria attained independence.16

3.3 Compulsory License under the Patent and Designs Act 1990:

Section 11 of the Patents and Designs Act postulates that the first schedule of the Act shall have effect regarding compulsory licenses. Paragraph 1 of the First Schedule of the Patents and Designs Act 1990 also states that "any time after the expiration of four years after the filing of a patent application or three years after the grant, whichever period last expires, a person may apply to the court for the grant of a compulsory licence..." The schedule goes further to provide four main grounds upon which a compulsory license could be granted. These are:

a. "that the patented invention being capable of being worked in Nigeria has not been so worked;

b. that the existing degree of working, of the patented invention in Nigeria does not meet, on reasonable terms, the demand for the product;

c. that the working of the patented invention in Nigeria is being hindered or prevented by the importation of the patented article; and

d. that, by reason of the refusal of the patentee to grant licences on reasonable terms, the establishment or development of industrial or commercial activities in Nigeria is unfairly and substantially prejudiced."

Furthermore, Paragraph 13 of the First Schedule empowers the Minister by order of the Gazette17 to grant compulsory licenses, for patented inventions that are of crucial importance for the "defense or the economy of Nigeria or for public health". Paragraph 13 in addition provides that compulsory licenses on these grounds may be permitted within the period stipulated in paragraph one and may also authorize importation.

Once a court hears a claim for the issuance of a compulsory license, the parties are allowed to agree upon the terms of such an arrangement. If they cannot agree, the court would then fix the terms, which includes the payment of adequate royalties taking into account "the extent to which the relevant invention is to be worked".18 Under the Patent and Designs Act 1990 the grant of compulsory license to any government agency is not automatic; the court must consider the application and decide whether the application is

3.4 Compulsory license under the Proposed IP Bill:

Similarly, the IP Bill 2008 makes provisions for the grant of compulsory licenses in its First Schedule. Notably, it expands the grounds laid down in the Patent and Designs Act, upon which such licenses may be granted. The Bill in addition to the non-working or insufficiency of working and refusal to deal grounds provided for in the Patent and Designs Act, has included anti-competitive, public interest and national emergency grounds.19 Furthermore, Paragraph 1(c) of the First Schedule explicitly stipulates that a compulsory license might be allowed to facilitate public health and nutrition and ensure that medicine is available to everyone.

3.5 Compulsory License under TRIPS:

One of the aims of the TRIPS Agreement was to ensure minimum standards between all trading systems that are members of GATT (The General Agreement on Tariffs and Trade)20 within the WTO. These minimum standards were especially targeted at the developing countries in an attempt to ensure that they make substantial changes to their laws.21 To achieve this, the TRIPS Agreement made several provisions and it appears that the most controversial are Articles 27 and 31, which are the provisions relating to compulsory licensing.22

Article 27 of the TRIPS Agreement explicitly provides that there will be no bias "as to the place of invention, the field of technology and whether products are imported or not". This provision would obviate the requirement that a patent must be worked in Nigeria in order for it to enjoy the monopoly right granted under the patent.23 This provision is therefore in conflict with the requirement prescribed in the First Schedule of the Patents and Designs Act 1990 that a compulsory license may be permitted over a patented invention which has not been operated in Nigeria. In Nigeria, the working of a patent has always been seen as the main justification for granting state monopoly to a patent and although the provision may appear to be burdensome to owners of patented inventions in technologically advanced countries, it is doubtful whether a total removal of the 'working' provision would benefit a developing country like Nigeria.24

Article 31 of the TRIPS Agreement states that "where the law of a Member allows for other use of the subject matter of a patent without the authorization of the right holder, including use by the government or third parties authorized by the government, the following provisions shall be respected:" Article 31 of TRIPS Agreement goes further to list certain onerous conditions25 before the patent could be used without the owner's approval, thus making the utilization of the compulsory licensing scheme imprecise. Furthermore, Article 31(b) of the TRIPS Agreement requires the intended user to make an effort to acquire authorization from the patent holder on commercial terms that are reasonable. However, Article 31(b) of the TRIPS Agreement also provides an opportunity for the Member to waive the requirement in extreme emergencies or in situations of public and non-commercial uses.

It has been suggested that licensing of patented technology from a developed country to a developing country would be prohibitively expensive and sometimes burdensome and that developing countries like Nigeria are better off taking advantage of the opportunity for compulsory licensing provided under Article 31 of the TRIPS Agreement.26

3.6 The Nigerian Healthcare Industry:

Initially, government and academic institutions funded scientific research and such research in the sciences was considered humanitarian or charitable. Consequently, the findings of researchers were made available to all. Also, the scientific community prior to 1980 frowned upon the privatization or commercialization of findings.27 More recently, with the increasing cost of producing new drugs and the need to invest in research to facilitate development in disease prevention and drug improvement, the researcher mostly relies upon the intervention of corporate bodies in funding research.28

Although these corporate bodies provide huge investments into medical research and facilitate drug development, they in turn expect profitable returns on their huge investments.29 One means through which a balance of R&D30 and profitability could be attained would be a provision protecting intellectual property rights in stipulated pharmaceutical products using the patent rights system.31

According to the WHO, in 2009 Nigeria's healthcare system ranked an abysmal 187th out of 191 members of the WHO.32 Furthermore, there is a growing trend of severe and life threatening ailments plaguing the Nigerian population currently. These aliments include non-contagious and contagious illnesses such as hypertension, cancer, diabetes and more recently EBOLA and Lassa fever, are offering enormous growth prospects for the pharmaceutical companies.33 The growth opportunities for pharmaceutical companies are gradually progressing from customary pharmaceutical markets (Europe and Latin America) controlled by conglomerates like Sanofi-Aventis, Novartis, Pfizer and GSK and are now expanding their global footprint into Africa.34

The IMS Health Market Prognosis Report35 ("the Report") shows that pharmaceutical expenditure in Africa by 2016 is anticipated to reach US$30 Billion. That Report indicates that:

"[T]his value is driven by a 10.6% compound annual growth rate (CAGR) through 2016, second only to Asia Pacific (12.5%) and in line with Latin America (10.5%) during this period."36 Furthermore, the report shows that "(W)hile continuing to struggle with infectious and parasitic illnesses, Africa is expected to experience the largest increase in death rates from cardiovascular (CV) disease, cancer, respiratory disease and diabetes, over the next ten years, resulting in greater demand for healthcare services and appropriate medicines. The combination of economic strength and an expanding middle class is already driving a demand for medicines across Africa."37

Moreover, according to the last National Census conducted in Nigeria, the Nigerian Population of about 140 Million is possibly the largest domestic market in Africa.38

3:7 Options available to Nigeria:

Over the years, Nigeria's pharmaceutical spending has risen by 16 percent compound annual growth rate (CAGR), nonetheless the high rates of effective pharmaceutical ingredients in Africa makes it impossible for most local enterprises to compete with Asian producers.39 With an increased number of Asian producers in Africa, the value of drugs being imported from India and China is twofold the market price, making it too expensive for the masses to have access to essential medicine.

It has been suggested that there are some options available to Nigeria to improve accessibility of Nigerians to medicines; two of these are compulsory licensing and parallel importation.40

Compulsory licensing as an Option

Paragraph 5 of the Doha Declaration recognizes compulsory licensing as a lawful and practical choice, which the Nigerian government can use to increase the supply of pharmaceuticals within the country. The Doha Declaration recognizes that public health calamities can be characterized as imminent national need or other situations of maximum emergency, which gives the government of developing countries the liberty to decide how and under what circumstances such licenses may be granted.41 Compulsory licensing is not restricted to only locally produced pharmaceuticals, it could also be applied to imported pharmaceuticals on a long-term or short-term basis.

It should be considered that in the long run the drugs might be less expensive if they are indigenously manufactured rather than transported across borders. However, the success of compulsory licensing is dependent upon adequate technical competence. In Nigeria, presently, only a limited number of local pharmaceutical firms possess the abilities to produce essential medicines for Nigeria, as only 30 percent of the essential medicines in Nigeria are produced locally.42 Considering this, it is essential that the Nigerian government look into authorizing more compulsory licenses in favour of local pharmaceutical companies with the capacity to manufacture essential drugs for the Nigerian populace.43

Parallel Importation as an Option

Like other manufacturing industries, in the pharmaceutical sector a system of differential pricing operates globally. Price differentiation is a strategy available to companies with monopolistic power allowing them to increase quantities sold without decreasing overall prices. As long as a company can segment the markets so that products targeted for one market, say the cheaper brand, do not leak into another market, the strategy becomes viable. Arguably, it benefits consumers because products which otherwise would not be sold at a lower price can reach them through market segmentation. Consequently, the costs of the similar medicine may vary in countries at the same time.44             

According to Correa, "The patent system is designed to enable patent holders to set prices higher than those that would be obtained in the competitive market."45 When a patent holder enjoys a monopoly over the drugs with respect to particular diseases with no alternative remedial options, the patent on the drug becomes an important factor in price determination for that drug.46

Thus, the parallel importation of patented drugs from a state where the drugs are less expensive would allow the importing country to purchase the drugs at lower price compared to if the drugs were imported directly. This contradicts the principle of market segmentation on which price discrimination functions.

The proposed Nigerian IP Bill 2008 (if and when implemented) would provide the opportunity for parallel importation based on its recommendation that the country adopts the international exhaustion doctrine. Parallel importation of drugs into the Nigerian market apart from enabling the drugs to be imported at a cheaper rate would also provide the importers with higher negotiating leverage with local and multinational manufacturers to accept lower prices.47 If the Nigerian government resorts to this option it must strengthen the administrative capacity for effective implementation by ensuring that the process for procuring licenses is transparent and manageable.48

Footnotes

* This paper is the second part to the series on the Effects of Parallel Importation in Nigeria.

* Yetunde Okojie LL.M (UCL), BL (Nig. Law Sch.) LL.B. (U.I). Associate at SPA Ajibade & Co, [Legal Practitioners, Arbitrators and Notaries Public].

3 Chapter P2 of the Laws of the Federation of Nigeria, (LFN) 2004. See Cecilia O 'Domestic Legislation and Court Decisions on Intellectual Property Rights and Public Health in Nigeria' (2011), p. 2 http://www.local-pharmaproduction.net/fileadmin/dateien/Country_studies/Country_analysis_-_Nigeria.pdf   accessed on 10 July 2014.

4 "Bill for an Act to provide for the Establishment of the Intellectual Property Commission of Nigeria, Repeal of Trademarks Act, Cap. T13, LFN 2004 and Patents and Designs Act, Cap. P2, LFN 2004 and Make Comprehensive Provisions for the Registration and Protection of Trademarks, Patents and Designs, Plant Varieties, Animal Breeders and Farmers Rights and for other Related Matters" (the IP Bill 2008).

5 Dr. Nguyen NhuQuynh, 'Parallel Trade of Patented Pharmaceuticals: A Discussion from Developing Country Perspective' (2014) Ministry of Science and Technology, p.2 http://iprenforcement.most.gov.vn/cac-bai-nghien-cuushtt/parallel-trade-of-patented-pharmaceuticals-a-discussion-from-developing-country-perspective   (accessed on June 4, 2014).

6 For more on domestic and territorial principles of exhaustion of rights, see Part 1 of the series on http://www.spaajibade.com/resources/wp-content/uploads/2016/03/Website-article-on-Parallel-Importation-and-the-Exhaustion-of-Rights-Principle-under-the-1.pdf

7 Section 6(3)(b) of the "Patents and Designs Act 1990".

8 Dr. Nguyen NhuQuynh, 'Parallel Trade of Patented Pharmaceuticals: A Discussion from Developing Country Perspective' (2014) Ministry of Science and Technology, p.5 http://iprenforcement.most.gov.vn/cac-bai-nghien-cuushtt/parallel-trade-of-patented-pharmaceuticals-a-discussion-from-developing-country-perspective (accessed on June 4, 2014).

9 No. 6 of 1925.

10 (1965) LLR 9.

11 The Act of 1949 is a United Kingdom Act and this 1949 Act has been repealed by a Patents Act of 1977 in the UK. The 1977 Act has also been amended severally, the last being in October 2014.

12 See Adebambo Adewopo, 'According to Intellectual Property: A Pro-Development Vision of the Law and the Nigerian Intellectual Property Law and Policy Reform in the Knowledge Era' (2012) p.47 NIALS http://nialsnigeria.org/PDFs/NIALS%205th%20Inaugural%20Lecture.pdf (accessed on 8th April July 2016).

13 No. 8 of 1968.

14 Olusegun Oyedepo, 'The Impact of TRIPS Agreement on the Patent Law in Nigeria' (2010) Department of Private Property, Law, Faculty of Law Kogi State University (CJPPL) Vol.2 Part 2 101, 102.

15 Charles Mwalimu The Nigeria Legal System, Volume 2 (Peter Lang, 2009) p. 519.

16 Olusegun Oyedepo, supra, (n. 14)

17 In Nigeria the appropriate Minister is the Minister of Trade and Tourism.

18 Paragraph 8 of the first Schedule of the Patent and Designs Act Cap. P2 LFN 2004.

19 Dr. Nguyen NhuQuynh, 'Parallel Trade of Patented Pharmaceuticals: A Discussion from Developing Country Perspective' (2014) Ministry of Science and Technology, p.6 http://iprenforcement.most.gov.vn/cac-bai-nghien-cuushtt/parallel-trade-of-patented-pharmaceuticals-a-discussion-from-developing-country-perspective  (accessed on June 4, 2014).

20 GATT covers, among other things, international trade in goods, the Council of the Trade in Goods, which is made up of representatives of all WTO members, is responsible for the workings of the GATT Agreement. For more see Matsushita et al, The World Trade Organization: Law, Practice and Policy (2nd edition Oxford International Law Library, 2006), p.702.

21 Olusegun Oyedepo, 'The Impact of TRIPS Agreement on the Patent Law in Nigeria' (2010) Department of Private Property, Law, Faculty of Law Kogi State University (CJPPL) Vol.2 Part 2 101, 103.

22 Ibid. p.104

23 Ibid.

24 Ibid.

25 These conditions are listed in Article 31(a)-(i) of the TRIPS Agreement.

26 Olusegun Oyedepo, 'The Impact of TRIPS Agreement on the Patent Law in Nigeria' (2010) Department of Private Property, Law, Faculty of Law Kogi State University (CJPPL) Vol.2 Part 2 101, 103.

27 T Lemmens, "Leopards in the Temple: Restoring Scientific Integrity to the Commercialized Research Scene," (2004) Journal of Law, Medicine and Ethics, 644.

28 T Bodenheimer, "Uneasy Alliance: Clinical Investigators and the Pharmaceutical Industry," vol 342 (no 20) Health Policy Report, 1539.

29 S Babafemi Odunsi, 'Pharmaceutical Industry, Patenting, Human Rights and Access to Treatment in Developing Countries: Another Look at Commercialization of Bio-Medical Research' (2002) Law Guru p.2 http://www.nigerianlawguru.com/articles/intellectual%20property%20law/PHARMACEUTICAL% 20INDUSTRY,%20PATENTING,%20HUMAN%20RIGHTS%20AND%20ACCESS%20TO%20TREATMENT %20IN%20DEVELOPING%20COUNTRIES,%20ANOTHER%20LOOK%20AT%20COMMERCIALIZATION% 20OF%20BIO%20MEDICAL%20RESEARCH.pdf  (accessed on 28 July 2014).

30 Research and Development

31 Ibid.

32 United Nations Industrial Development Organization, Pharmaceutical Sector Profile: Nigeria: Strengthening the Local production of essential Generic Drugs in Least Developed and Developing Countries (2011) p.6 http://www.unido.org/fileadmin/user_media/Services/PSD/BEP/Nigeria_Pharma%20Sector%20Profile_032011_Ebook.pdf (accessed on 28 July 2014).

33 Alexander Chiejina 'Pharmaceutical Firms Profit from Rising Disease Burden' (2013) INTEL http://www.nigeriaintel.com/2013/07/01/pharmaceutical-firms-profit-from-rising-disease-burden/ (accessed on July 12 2014).

34 Ibid.

35 IMS health is a leading provider of information, services and technology from the healthcare industry around the world.

36 IMS Health Market Prognosis Report, Africa: A Ripe Opportunity Understanding the Pharmaceutical Market Opportunity and Developing Sustainable Business Models in Africa (White Paper Africa, AFRCWP1112) p.2. http://www.imshealth.com/ims/Global/Content/Insights/Featured%20Topics/Emerging%20Markets/IMS_Africa_Opportunity_Whitepaper.pdf (accessed on 24 July 2014).

37 Ibid p. 3.

38 Ibid p.3.

39 Ibid.

40 For more see Ayodele A Adewole ' Globalization, The TRIPS Agreement and Their Implications on Access to Essential Medicine for Developing Countries: A Case Study of Nigeria' (2010) p. 187 NIALS http://nialsnigeria.org/pub/AyodeleA.pdf (accessed on 14 July 2014).

41 Ibid p.188.

42 Victoria Ojeme 'Nigeria Has Low Drugs Manufacturing Capacity- NAFDAC DG' Vanguard (Nigeria, 10 July 2014) http://www.vanguardngr.com/2013/07/nigeria-has-low-drugs-manufacturing-capacity-nafdac-dg/ (accessed on 24 July 2014).

43 IMS Health Market Prognosis Report, Africa: A Ripe Opportunity Understanding the Pharmaceutical Market Opportunity and Developing Sustainable Business Models in Africa (White Paper Africa, AFRCWP1112) p.187. http://www.imshealth.com/ims/Global/Content/Insights/Featured%20Topics/Emerging%20Markets/IMS_Africa_Oppo rtunity_Whitepaper.pdf (accessed on 24 July 2014).

44 ibid p.189.

45 C M Correa, Implications of the Doha Declaration on the TRIPS Agreement and Public Health, Geneva: World Health Organization, 2002, p5.

46 Third World Network, TRIPS, Patents and Access to Medicines: Proposals for Clarification and Reform – (TWN Briefing Paper; June, 2001), pp. 5-6.

47 IMS Health Market Prognosis Report, Africa: A Ripe Opportunity Understanding the Pharmaceutical Market Opportunity and Developing Sustainable Business Models in Africa (White Paper Africa, AFRCWP1112) p.189. http://www.imshealth.com/ims/Global/Content/Insights/Featured%20Topics/Emerging%20Markets/IMS_Africa_Oppo rtunity_Whitepaper.pdf (accessed on 24 July 2014).

48 Ibid.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.